Malaria Vaccine Development Using Bacterial Flagellin
Author Information
Author(s): Daniel Y. Bargieri, Irene S. Soares, Fabio T. M. Costa, Catarina J. Braga, Luis C. S. Ferreira, Mauricio M. Rodrigues
Primary Institution: Universidade Federal de São Paulo
Hypothesis
Can bacterial flagellin fusion proteins enhance the effectiveness of malaria vaccines in humans?
Conclusion
Bacterial flagellins should be considered for malaria vaccine formulations to improve their effectiveness in humans.
Supporting Evidence
- Bacterial flagellins activate immune responses in both mice and humans.
- RTS,S is the most advanced malaria vaccine candidate but has limitations.
- Flagellin fusion proteins have shown promise in preclinical studies.
Takeaway
Researchers are trying to use a part of bacteria called flagellin to help make better malaria vaccines for people.
Methodology
The review discusses various vaccine formulations and their effectiveness based on animal models and early human trials.
Limitations
Many vaccine formulations that work in mice do not produce the same immune response in humans.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website